1. Clinical trials in cardiac xenotransplantation: Are we ready to overcome barriers?
- Author
-
André Monti Garzesi, Leonardo A. M. Zornoff, Bertha F. Polegato, Flávio de Souza Brito, Marcos F. Minicucci, Leonardo Rufino Garcia, Marcello Laneza Felicio, and Márcia Terezinha Tardivo
- Subjects
Graft Rejection ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Cardiovascular pathology ,Xenotransplantation ,medicine.medical_treatment ,Transplantation, Heterologous ,Cardiovascular research ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Informed consent ,medicine ,Animals ,Humans ,Intensive care medicine ,business.industry ,medicine.disease ,Ventricular assistance ,Clinical trial ,030228 respiratory system ,Heart failure ,Heart Transplantation ,Heterografts ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Allotransplantation - Abstract
Heart allotransplantation has become one of the methods of choice in the treatment of severe heart failure. In the face of its difficulties, such as the unmet balance between organ supply and demand, the use of xenotransplantation (XTx) might be an attractive option shortly, even more with the ongoing progress achieved regarding the avoidance of hyperacute rejection and primary organ disfunction, maintenance of xenograft function and control of xenograft growth. To make possible this translational challenge, some points must be taken into account indeed, and they are the equipoise of human benefit and animal suffering, the risk of unknown infections, a well prepared informed consent, ethical and religious beliefs, and the role of cardiac XTx in a ventricular assistance device era.
- Published
- 2021
- Full Text
- View/download PDF